MX338489B - Derivados de hidantoina utiles como inhibidores de kv3. - Google Patents

Derivados de hidantoina utiles como inhibidores de kv3.

Info

Publication number
MX338489B
MX338489B MX2013006343A MX2013006343A MX338489B MX 338489 B MX338489 B MX 338489B MX 2013006343 A MX2013006343 A MX 2013006343A MX 2013006343 A MX2013006343 A MX 2013006343A MX 338489 B MX338489 B MX 338489B
Authority
MX
Mexico
Prior art keywords
inhibitors
derivatives useful
hydantoin derivatives
hydantoin
compounds
Prior art date
Application number
MX2013006343A
Other languages
English (en)
Other versions
MX2013006343A (es
Inventor
Giuseppe Alvaro
Charles Large
Agostino Marasco
Anne Decor
Paolo Dambruoso
Simona Tommasi
Original Assignee
Autifony Therapeuticts Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2010/068946 external-priority patent/WO2011069951A1/en
Priority claimed from GBGB1020607.6A external-priority patent/GB201020607D0/en
Priority claimed from GBGB1109508.0A external-priority patent/GB201109508D0/en
Priority claimed from GBGB1113757.7A external-priority patent/GB201113757D0/en
Application filed by Autifony Therapeuticts Ltd filed Critical Autifony Therapeuticts Ltd
Publication of MX2013006343A publication Critical patent/MX2013006343A/es
Publication of MX338489B publication Critical patent/MX338489B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención proporciona compuestos de fórmula (I): (Ver Formula) dichos compuestos son inhibidores de canales Kv3 y de uso en la profilaxis o el tratamiento de trastornos relacionados.
MX2013006343A 2010-12-06 2011-12-06 Derivados de hidantoina utiles como inhibidores de kv3. MX338489B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2010/068946 WO2011069951A1 (en) 2009-12-11 2010-12-06 Imidazolidinedione derivatives
GBGB1020607.6A GB201020607D0 (en) 2010-12-06 2010-12-06 Novel compounds
GBGB1109508.0A GB201109508D0 (en) 2011-06-07 2011-06-07 Novel compounds
GBGB1113757.7A GB201113757D0 (en) 2011-08-10 2011-08-10 Novel compounds
PCT/GB2011/052414 WO2012076877A1 (en) 2010-12-06 2011-12-06 Hydantoin derivatives useful as kv3 inhibitors

Publications (2)

Publication Number Publication Date
MX2013006343A MX2013006343A (es) 2013-09-13
MX338489B true MX338489B (es) 2016-04-18

Family

ID=45464001

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006343A MX338489B (es) 2010-12-06 2011-12-06 Derivados de hidantoina utiles como inhibidores de kv3.

Country Status (17)

Country Link
US (13) US9346790B2 (es)
EP (1) EP2649066B1 (es)
JP (2) JP5913357B2 (es)
KR (1) KR101862375B1 (es)
CN (1) CN103328467B (es)
AU (1) AU2011340258C1 (es)
BR (1) BR112013013914B1 (es)
CA (1) CA2817205C (es)
DK (1) DK2649066T3 (es)
EA (2) EA023768B1 (es)
ES (1) ES2560304T3 (es)
IL (3) IL226256A0 (es)
MX (1) MX338489B (es)
PL (1) PL2649066T3 (es)
SG (2) SG190203A1 (es)
WO (1) WO2012076877A1 (es)
ZA (1) ZA201403529B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011069951A1 (en) * 2009-12-11 2011-06-16 Glaxo Group Limited Imidazolidinedione derivatives
KR101862375B1 (ko) 2010-12-06 2018-05-29 오티포니 세라피틱스 리미티드 Kv3 억제제로서 유용한 하이단토인 유도체
GB201209986D0 (en) 2012-06-06 2012-07-18 Autifony Therapeutics Ltd Novel compounds
US9193704B2 (en) 2011-06-07 2015-11-24 Autifony Therapeutics Limited Hydantoin derivatives as KV3 inhibitors
CN103974944B (zh) 2011-12-06 2016-11-02 奥蒂福尼疗法有限公司 用作kv3抑制剂的乙内酰脲衍生物
BR112014028718A2 (pt) * 2012-05-22 2017-06-27 Autifony Therapeutics Ltd derivados de hidantoína como inibidores de kv3
BR112014028991A2 (pt) 2012-05-22 2017-06-27 Autifony Therapeutics Ltd triazóis como inibidores de kv3
WO2013182851A1 (en) * 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required
PL3092234T3 (pl) * 2013-12-20 2018-07-31 Gilead Sciences, Inc. Skondensowane związki heterocykliczne jako modulatory kanałów jonowych
TWI669295B (zh) 2014-01-16 2019-08-21 美商艾佛艾姆希公司 作為除草劑的嘧啶氧基苯衍生物
EP3120140B1 (en) * 2014-03-21 2018-10-31 Biotage AB Method and apparatus for the equilibration of a packed chromatography column
CN103980205B (zh) * 2014-06-05 2016-01-20 武汉格罗宁根医药科技有限公司 N-3-取代磺酰胺乙基-5-环丙烷螺环乙内酰脲衍生物及其制备方法和应用
TWI828952B (zh) 2015-06-05 2024-01-11 美商艾佛艾姆希公司 作為除草劑之嘧啶氧基苯衍生物
GB201521751D0 (en) * 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201522179D0 (en) * 2015-12-16 2016-01-27 Autifony Therapeutics Ltd Novel compounds
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
US20200039970A1 (en) 2016-12-16 2020-02-06 Autifony Therapeutics Limited Hydantoin modulators of kv3 channels
TW201904947A (zh) * 2017-05-02 2019-02-01 美商富曼西公司 作為除草劑的嘧啶氧基苯稠合化合物
WO2018220762A1 (ja) * 2017-05-31 2018-12-06 大塚製薬株式会社 ピリミジン化合物
CN107556262B (zh) * 2017-08-14 2020-05-22 四川大学 一种2-取代基芳并噁唑的制备方法
DE112018007799T5 (de) 2018-07-03 2021-03-25 Cummins Emission Solutions Inc. Zersetzungsreaktor mit körpermischung
US12358901B2 (en) 2018-10-16 2025-07-15 Autifony Therapeutics Limited KV3 modulators
SI3867247T1 (sl) * 2018-10-16 2024-11-29 Autifony Therapeutics Limited Nove spojine
MY210184A (en) 2018-11-30 2025-08-31 Otsuka Pharma Co Ltd Heterocyclic compounds for the treatment of epilepsy
GB201821066D0 (en) * 2018-12-21 2019-02-06 Univ Oxford Innovation Ltd Sleep modulation
JP7551641B2 (ja) * 2019-03-25 2024-09-17 バイオノミクス リミテッド 置換ｎ－ヘテロアリール化合物及びその使用
EP4100402A1 (en) 2020-02-06 2022-12-14 Autifony Therapeutics Limited Kv3 modulators
US11638606B2 (en) 2020-04-15 2023-05-02 Bard Peripheral Vascular, Inc. Bipolar electrosurgical pleura sealing device, system, and method of operating same
EP3901152A1 (en) 2020-04-23 2021-10-27 F. Hoffmann-La Roche AG Kv3 enhancers for the treatment of cognitive disorders
CN112213428A (zh) * 2020-10-13 2021-01-12 辽宁科技大学 一种超临界co2中进行非催化乙酰基化反应及其在线检测方法
KR20240046748A (ko) 2021-08-10 2024-04-09 오티포니 세라피틱스 리미티드 칼륨 채널 조절제
WO2023101418A1 (ko) * 2021-12-03 2023-06-08 (주)인비보텍 난청 또는 이명의 예방 또는 치료용 조성물
EP4630117A1 (en) 2022-12-06 2025-10-15 Autifony Therapeutics Limited Compounds for the treatment of centra nervous system disorders

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3474170A (en) * 1964-01-23 1969-10-21 Fmc Corp Pesticidal carbamates of dihydrobenzofuranols
US4143055A (en) * 1978-03-27 1979-03-06 Gruppo Lepetit S.P.A. 2,4,6-trisubstituted-2,3-dihydro-benzofuran derivatives
DE3015090A1 (de) 1980-04-19 1981-10-22 Basf Ag, 6700 Ludwigshafen ]-(trihalogenmethyl-sulfenyl)-4-aryl-1,2,4-triazolidin-5-one, verfahren zu ihrer herstellung, diese enthaltende fungizide und verfahren zur bekaempfung von pilzen mit diesen verbindungen
DE3133405A1 (de) 1981-08-24 1983-03-10 Basf Ag, 6700 Ludwigshafen 1-(trihalogenmethyl-sulfenyl)-4-aryl-1,2,4-triazolidin-5-one und diese enthaltende fungizide
US4675403A (en) 1985-10-16 1987-06-23 American Home Products Corporation 3-Aminoalkyl derivatives of 5,5-disubstituted hydantoins with psychotropic activity
JP2514945B2 (ja) * 1987-02-05 1996-07-10 三井石油化学工業株式会社 芳香族アミン誘導体
DE3810848A1 (de) 1988-03-30 1989-10-19 Boehringer Ingelheim Kg Neue 2,3,4-substituierte imidazole und 3,4,5-substituierte 1,2,4-triazole, ihre herstellung und verwendung
DE3836175A1 (de) 1988-10-24 1990-05-03 Bayer Ag Fluor enthaltende phenole
CA2007830A1 (en) * 1989-01-18 1990-07-18 Shuji Ozawa 2,3-dihydro-3, 3-dimethyl-5-trifluoromethanesulfonyloxy-benzofurans, process for producing them and herbicides containing them
WO1991004027A1 (en) 1989-09-15 1991-04-04 Pfizer Inc. New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat)
JPH03153606A (ja) * 1989-11-10 1991-07-01 Mitsui Petrochem Ind Ltd 除草剤組成物
US5362878A (en) 1991-03-21 1994-11-08 Pfizer Inc. Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
DK123493D0 (da) 1993-11-01 1993-11-01 Lundbeck & Co As H Compounds
WO1996036229A1 (en) 1995-05-17 1996-11-21 E.I. Du Pont De Nemours And Company Fungicidal cyclic amides
MX9708802A (es) 1995-05-17 1998-02-28 Du Pont Amidas ciclicas fungicidas.
EP0836384A1 (en) 1995-06-20 1998-04-22 E.I. Du Pont De Nemours And Company Arthropodicidal and fungicidal cyclic amides
CN1231663A (zh) 1996-08-01 1999-10-13 纳幕尔杜邦公司 杀节肢动物剂和杀真菌剂环酰胺
KR20000057254A (ko) 1996-11-26 2000-09-15 메리 이. 보울러 메틸 치환된 살진균제 및 살절지동물제
WO1998023155A1 (en) 1996-11-26 1998-06-04 E.I. Du Pont De Nemours And Company Arthropodicidal and fungicidal cyclic amides
AU6040398A (en) 1997-01-30 1998-08-25 E.I. Du Pont De Nemours And Company Fungicidal compositions
JP4171549B2 (ja) 1998-01-28 2008-10-22 大正製薬株式会社 含フッ素アミノ酸誘導体
JP2000072731A (ja) 1998-08-31 2000-03-07 Taisho Pharmaceut Co Ltd ４−置換−２−アミノビシクロ［３．１．０］ヘキサン−２，６−ジカルボン酸誘導体及び製薬用組成物
JP4194715B2 (ja) 1998-08-31 2008-12-10 大正製薬株式会社 ６−フルオロビシクロ［３．１．０］ヘキサン誘導体
EP1206935A4 (en) 1999-07-23 2008-07-30 Shionogi & Co TH2 DIFFERENTIAL INHIBITION
AU2001244614A1 (en) 2000-04-04 2001-10-15 Shionogi & Co., Ltd. Oily compositions containing highly fat-soluble drugs
WO2001076582A1 (fr) 2000-04-05 2001-10-18 Shionogi & Co., Ltd. Micro-emulsions huile dans eau contenant des composes tricycliques ou des preconcentres de ceux-ci
FR2812633A1 (fr) 2000-08-04 2002-02-08 Aventis Cropscience Sa Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides
WO2003048134A1 (en) 2001-12-05 2003-06-12 Japan Tobacco Inc. Triazole compound and medicinal use thereof
CA2475767A1 (en) 2002-02-07 2003-08-14 The Curators Of The University Of Missouri Opioid receptor active 4-(3-hydroxyphenyl) or 4-(3-alkoxyphenyl)-1,2,4-triazole compounds
FI20030030A0 (fi) * 2003-01-09 2003-01-09 Orion Corp Uusia yhdisteitä
US20050009817A1 (en) 2003-04-30 2005-01-13 Jennifer Savoy Substituted heteroaryls
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
GB0325175D0 (en) 2003-10-28 2003-12-03 Novartis Ag Organic compounds
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
US20060211697A1 (en) 2004-12-08 2006-09-21 Liren Huang 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents
KR101579701B1 (ko) 2005-05-13 2015-12-22 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
DK2656842T3 (en) 2006-03-27 2016-11-07 Univ California Androgen receptor MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND androgen receptor-ASSOCIATED DISEASES
EP3020706A1 (en) 2006-03-29 2016-05-18 The Regents Of The University Of California Diarylthiohydantoin compounds useful for the treatment of a hyperproliferative disorder
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
US20080269267A1 (en) 2007-04-20 2008-10-30 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoprolific diseases and other proliferative diseases
EP2252592A1 (de) 2008-02-07 2010-11-24 Sanofi-Aventis Arylchalcogeno-arylalkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
AU2009289846B2 (en) * 2008-09-02 2014-10-16 Sanofi-Aventis Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof
US8178547B2 (en) * 2008-12-22 2012-05-15 Roche Palo Alto Llc Heterocyclic antiviral compounds
WO2011069951A1 (en) * 2009-12-11 2011-06-16 Glaxo Group Limited Imidazolidinedione derivatives
EP2513092A1 (en) * 2009-12-14 2012-10-24 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
KR101862375B1 (ko) * 2010-12-06 2018-05-29 오티포니 세라피틱스 리미티드 Kv3 억제제로서 유용한 하이단토인 유도체
US9193704B2 (en) 2011-06-07 2015-11-24 Autifony Therapeutics Limited Hydantoin derivatives as KV3 inhibitors
JP2018533579A (ja) 2015-10-30 2018-11-15 ザ・ジョンズ・ホプキンス・ユニバーシティー 高分子量かつ密な被覆を有する粘液浸透粒子

Also Published As

Publication number Publication date
KR20130138815A (ko) 2013-12-19
US9346790B2 (en) 2016-05-24
EA027532B1 (ru) 2017-08-31
IL253102B (en) 2018-04-30
AU2011340258A1 (en) 2013-05-30
EP2649066B1 (en) 2015-10-21
BR112013013914B1 (pt) 2021-10-26
US11541052B2 (en) 2023-01-03
IL253104A0 (en) 2017-08-31
US20200360379A1 (en) 2020-11-19
US20190192516A1 (en) 2019-06-27
AU2011340258B2 (en) 2016-05-19
EA201390609A1 (ru) 2014-01-30
US20140323508A1 (en) 2014-10-30
US9422272B2 (en) 2016-08-23
US11583527B2 (en) 2023-02-21
EA023768B1 (ru) 2016-07-29
IL226256A0 (en) 2013-07-31
EP2649066A1 (en) 2013-10-16
US10835534B2 (en) 2020-11-17
US10555945B2 (en) 2020-02-11
EA201490922A1 (ru) 2015-03-31
CA2817205A1 (en) 2012-06-14
JP2013544873A (ja) 2013-12-19
ES2560304T3 (es) 2016-02-18
MX2013006343A (es) 2013-09-13
US11197859B2 (en) 2021-12-14
DK2649066T3 (en) 2016-01-11
KR101862375B1 (ko) 2018-05-29
CN103328467B (zh) 2016-08-10
JP2016145215A (ja) 2016-08-12
US20170273981A1 (en) 2017-09-28
US20210023084A1 (en) 2021-01-28
US20190000849A1 (en) 2019-01-03
SG11201402529RA (en) 2014-06-27
US20150336936A1 (en) 2015-11-26
US20180036308A1 (en) 2018-02-08
US20130267510A1 (en) 2013-10-10
HK1190395A1 (en) 2014-07-04
US10098881B2 (en) 2018-10-16
CA2817205C (en) 2020-04-07
ZA201403529B (en) 2020-03-25
SG190203A1 (en) 2013-06-28
US10265316B2 (en) 2019-04-23
US20220054490A1 (en) 2022-02-24
CN103328467A (zh) 2013-09-25
JP5913357B2 (ja) 2016-04-27
IL253102A0 (en) 2017-08-31
US20200179385A1 (en) 2020-06-11
US9133175B2 (en) 2015-09-15
US20160251340A1 (en) 2016-09-01
JP6118927B2 (ja) 2017-04-19
BR112013013914A2 (pt) 2016-09-13
PL2649066T3 (pl) 2017-04-28
AU2011340258C1 (en) 2016-10-20
US20160317537A1 (en) 2016-11-03
US9833452B2 (en) 2017-12-05
WO2012076877A1 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
MX338489B (es) Derivados de hidantoina utiles como inhibidores de kv3.
MX356813B (es) Derivados de hidantoina utiles como inhibidores de kv3.
IN2015DN01156A (es)
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
PH12012500674A1 (en) Heterocyclic compounds useful as pdk1 inhibitors
JO2892B1 (en) CYP inhibitors 17
CA2871471C (en) Dna-pk inhibitors
PH12013500870A1 (en) Heterocyclic compounds and uses thereof
EA201170832A1 (ru) Пуриновые соединения
MY165620A (en) Cyclopropylamines as lsd1 inhibitors
TN2011000673A1 (en) Bace inhibitors
UA105911C2 (uk) Сульфонамідні похідні
MX2016000646A (es) Sulfonamidas como moduladores de canales de sodio.
UA104885C2 (uk) Ізотіазолілоксифеніламідини та їх застосування як фунгіцидів
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
MX2012004780A (es) Inhibidores de akt.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
EP2603216A4 (en) HETEROARYLE AND USES THEREOF
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
MX342947B (es) Tratamiento de diabetes tipo 2.
CA2887539C (en) Azaquinazoline carboxamide derivatives
MX2013002121A (es) Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
EA201270728A1 (ru) Пуриновые соединения
UA109793C2 (uk) Арилсульфонаміди для лікування захворювань центральної нервової системи (цнс)

Legal Events

Date Code Title Description
FG Grant or registration